CSIR launches India’s first anti diabetic ayurvedic drug BGR -34
The Council for Scientific and Industrial Research (CSIR) has launched BGR-34, an anti-diabetic ayurvedic drug designed for type 2 Diabetes mellitus.
The anti-diabetic ayurvedic drug BGR-34 has been jointly developedby National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP).
- BGR-34 works by controlling blood sugar and limiting the harmful effects and toxicity of other drugs.
- It contains 34 identified active phyto-constitutes from herbal resources.
- It has been economically priced at 5 rupees per tablet as compared to latest DPP4 inhibitors globally.
About Council of Scientific and Industrial Research (CSIR)
- CSIR is an autonomous body and the largest research and development (R&D) organisation in India.
- It was established in 1942. It operates as an autonomous body registered under the Registration of Societies Act of 1860.
- It is mainly funded by the Union Ministry of Science and Technology.
- CSIR’s R&D activities include aerospace engineering, ocean sciences, structural engineering, metallurgy, life sciences, chemicals, mining, food, petroleum, leather, and environment.